Puma pharmaceuticals 2025
Puma pharmaceuticals 2025
Puma pharmaceuticals 2025
Puma pharmaceuticals 2025
Puma pharmaceuticals 2025
Puma pharmaceuticals 2025

Puma pharmaceuticals 2025

Puma pharmaceuticals 2025, Puma Biotechnology Biotechnology The Pharmaletter The Pharmaletter 2025

$39.00

SKU: 7511752

Colour
  • Puma Biotechnology Inc
  • Puma Biotechnology Announces Initiation of ALISCA Breast1 Phase II Trial of Alisertib in Hormone Receptor Positive HER2 Negative Metastatic Breast Cancer Business Wire
  • Puma Biotechnology Biotechnology The Pharmaletter The Pharmaletter
  • Puma Biotech anti HER2 breast cancer drug approved in China BioTuesdays
Out of stock
Personalised:
: ( x )
Personalisation:
Edit
Remove Personalisation
Frasers Plus

Buy now.

Pay later.

Earn rewards

Representative APR: 29.9% (variable)

Credit subject to status. Terms apply.

Missed payments may affect your credit score

FrasersPlus